Novo Nordisk Plans Cautious Wegovy Launch in China to Preserve Global Supply
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a leading healthcare company, has reportedly planned a cautious...
Drug
Hybio Pharmaceutical Gets FDA Nod for Tirzepatide Raw Materials in DMF Filing
Hybio Pharmaceutical Co., Ltd (SHE: 300199), a Chinese pharmaceutical company, has announced that it has...
Abbisko Therapeutics Presents Positive Phase II Results for HCC Treatment at ESMO-GI
Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotech company, has announced the presentation of...
Dizal Pharmaceutical’s Golidocitinib Breaks Record with Rapid Market Launch in China
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a biopharmaceutical company based in China, has seen its...
HighTide Therapeutics Completes Enrollment for Two Phase III Trials of T2DM Drug Candidate HTD1801
HighTide Therapeutics Inc., (HKG: 2511), a biopharmaceutical company based in China, has announced the completion...
Shanghai Junshi Biosciences’ Toripalimab Gains NMPA Nod for First-Line TNBC Treatment
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that it has received...
Harbour BioMed Resubmits Biological License Application for Batoclimab in China
Harbour BioMed (HKG: 2142), a biopharmaceutical company with operations in the United States, the Netherlands,...
Antengene’s Xpovio Included in South Korea’s NHIS Reimbursement Drug List
Antengene Corp., Ltd (HKG: 6996), a biopharmaceutical company based in China, has announced that South...
Bio-Thera Solutions’ BAT1806 Biosimilar Receives European Commission Approval
Bio-Thera Solutions Ltd (SHA: 688177), a biopharmaceutical company based in China, has announced that it...
Novartis’s Scemblix STAMP Inhibitor for CML Accepted for Review by China’s NMPA
Novartis (NYSE: NVS), the Swiss pharmaceutical giant, has had its market filing for Scemblix (asciminib)...
Novo Nordisk’s Ocedurenone Misses Primary Endpoint in Chronic Kidney Disease Trial
Novo Nordisk (NYSE: NVO; CPH: NOVO-B), a Danish pharmaceutical company, has announced that its pipeline...
Merck’s HER3-Targeted ADC Patritumab Deruxtecan Faces FDA Complete Response Letter
Merck, Sharp & Dohme Inc. (NYSE: MRK), a leading U.S. pharmaceutical company, has announced that...
Moderna’s RSV Vaccine Efficacy Wanes to 50% After 18 Months, Shares Slide
Moderna Inc. (NASDAQ: MRNA), a U.S.-based biopharmaceutical company, has announced long-term efficacy data for its...
J&J Halts Mid-Stage Trial for Tremfya in Giant Cell Arteritis Due to Efficacy Concerns
Johnson & Johnson (J&J; NYSE: JNJ), a leading U.S.-based healthcare company, has reportedly discontinued a...
AstraZeneca’s Tagrisso Wins NMPA Approval for First-Line EGFR-mutated NSCLC Treatment
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical company, has announced that it has received another...
Sino Biopharmaceutical Gains NMPA Approval for Liraglutide Biosimilar for Type 2 Diabetes
Sino Biopharmaceutical Ltd (HKG: 1177), a major player in China’s pharmaceutical industry, has announced that...
CSPC Pharmaceutical’s BCMA-Targeted CAR-T Therapy SYS6020 Receives NMPA Clinical Trial Approval
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Novo Nordisk’s Semaglutide for Long-Term Weight Management Receives NMPA Approval
Novo Nordisk (NYSE: NVO, CPH: NOVO-B), a leading healthcare company from Denmark, has announced that...
Jiangsu Simcere Pharmaceutical Wins NMPA Nod for Biosimilar Version of Erbitux
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096), a Chinese pharmaceutical company, has announced that it...
Merck KGaA’s Xevinapant Misses Primary Endpoint in Phase III Head and Neck Cancer Trial
Merck KGaA (NYSE: MRK), a leading German pharmaceutical company, has encountered a setback in the...